Skip to main content
Caplight Logo









Augustine Therapeutics

Augustine Therapeutics

Private
LeuvenHealthcare & Life Scienceshttps://www.augustinetx.com/

Last Round

Series A

Mar 24, 2025

Total Funding Raised

$108.08M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Augustine Therapeutics is a biotechnology company that develops therapeutic drugs designed to treat neuromuscular and neurodegenerative diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

HDAC6 inhibitorssmall molecule drugsCharcot-Marie-Tooth diseaseCMTneuromuscular disease treatmentselective HDAC6 inhibitorclinical stage biotechrare disease therapeuticsdrug discoveryneurodegenerative disease treatmentperipheral nerve disorderpharma licensingALS treatmentcardiometabolic disease

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Augustine Therapeutics Comparables

Compare Augustine Therapeutics with similar companies based on industry and business-model similarity.

Augustine Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Regenacy Pharmaceuticals
87%
Eikonizo Therapeutics
85%
HDAX Therapeutics
83%

Augustine Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMar 24, 2025
Series AJun 26, 2024
SeedFeb 26, 2020

Key People

Founding team and executive leadership

Gerhard Koenig

Chief Executive Officer

Executive Team

Augustine Therapeutics Investors

Notable investors and investment history

Augustine Therapeutics investors
InvestorRounds
Asabys PartnersSeries A
Newton BiocapitalSeries A
KU Leuven Research & Development (LRD)Seed, Series A
V-Bio VenturesSeries A, Seed
Novo HoldingsSeries A
PMVSeed, Series A
VIBSeed, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased from 0 to 6, representing 25% of headcount.

  • Jan 20, 2026

    Monthly visitors grew 406% MoM, reaching 3.1K.

Augustine Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Augustine Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Augustine Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLeuven
Employee Range23
Year Founded2019
Last FundingMar 24, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?